NCT03330847 2026-03-10To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZenecaPhase 2 Active not recruiting273 enrolled 22 charts
NCT02482311 2023-07-03Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed92 enrolled
NCT03012477 2021-11-23CISPLATIN + AZD-1775 In Breast CancerDana-Farber Cancer InstitutePhase 2 Completed34 enrolled 9 charts